AOD-9604 occupies an awkward middle ground in the fat-loss category, and the honest comparison depends entirely on the comparator. Against the FDA-approved GLP-1 receptor agonists it is not a peer; against the obscure research chemicals that circulate with almost no human data it looks comparatively well-studied. What separates it from most gray-market peptides is a real, funded development program that was later discontinued after mid-stage human trials failed to separate it from placebo.
AOD-9604 is a discontinued synthetic hGH fragment with no weight-loss approval, better documented than obscure research peptides but far weaker in evidence, safety oversight, and demonstrated effect than the FDA-approved GLP-1 agonists that produce 10 to 20 percent body-weight loss.
GLP-1 receptor agonists and AOD-9604 diverge on mechanism, effect size, and evidence, and the gap widens at each. The GLP-1 drugs act on the incretin system to slow gastric emptying and blunt appetite, driving a large drop in caloric intake, while AOD-9604 was designed to mimic the lipolytic tail region of growth hormone and act on fat metabolism directly. The two evidence bases are not comparable in scale or rigor.
| Dimension | GLP-1 agonists (semaglutide, tirzepatide) | AOD-9604 |
|---|---|---|
| Mechanism | Incretin system: slows gastric emptying, blunts appetite | Mimics lipolytic hGH fragment, acts on fat metabolism |
| Weight loss | ~10 to 20% of body weight in pivotal trials | Did not beat placebo in mid-stage trials |
| Evidence base | Tens of thousands of participants across RCTs | Small, ultimately discontinued program |
| Regulatory status | Approved for chronic weight management | No weight-loss approval |
Semaglutide and tirzepatide produced roughly 10 to 20 percent body-weight loss across tens of thousands of randomized participants and hold FDA approval for chronic weight management, while AOD-9604 failed to beat placebo in its small, discontinued mid-stage program.
The whole point of AOD-9604 is structural. It is the C-terminal fragment corresponding roughly to amino acids 176 to 191, engineered to isolate growth hormone's fat-mobilizing action while leaving out the growth-promoting and IGF-1-raising effects that create clinical risk. On paper that separates it both from full growth hormone and from the secretagogues that prompt the entire hormone cascade.
AOD-9604 is the C-terminal hGH fragment (roughly amino acids 176 to 191) engineered to reproduce growth hormone's lipolytic action without its IGF-1-raising, glucose-disturbing, and tissue-growth effects, a selectivity shown in animal models but never converted into a proven human advantage.
By the one standard that matters for a weight-loss drug, whether it beats placebo in well-run human trials, AOD-9604's evidence is weak. The compound advanced into human testing, including a Phase II obesity study, but the results did not show weight loss meaningfully greater than placebo, and its development as an anti-obesity injectable was discontinued. The approved weight-loss drugs cleared exactly the bar AOD-9604 did not.
AOD-9604 advanced to a Phase II obesity trial but did not produce weight loss meaningfully greater than placebo and was discontinued, leaving no positive, replicated, adequately powered human trial to place it near the approved weight-loss drugs.
The selectivity argument rests on a specific hypothesis about which part of growth hormone does what. Researchers proposed that the fat-metabolizing activity of growth hormone is concentrated in its C-terminal region, so a short fragment mimicking that region should stimulate lipolysis without the domains responsible for the hormone's other effects. That story held together in cells and animals; it did not hold in people.
AOD-9604's selectivity hypothesis, that a C-terminal hGH fragment could stimulate lipolysis without raising IGF-1 or disturbing glucose, held in cell and animal models but did not prove out in human trials, where the predicted weight loss failed to materialize.
AOD-9604's staying power comes from its backstory rather than its results. Unlike the many obscure research chemicals that circulate with almost no human data, it was a genuinely funded pharmaceutical candidate that went through formal development and human obesity trials. In marketing terms a paper trail reads as credibility even when the trial results were negative.
AOD-9604 endures in the gray-market fat-loss space because it was a funded pharmaceutical candidate with formal human obesity trials, a paper trail that reads as credibility even though those trials were negative and it holds no weight-loss approval.
Placing AOD-9604 among the other peptides marketed for fat loss mainly exposes how uneven the category is. It ranges from a compound with an actual approved indication down to chemicals sold purely on a plausible mechanism, and AOD-9604 lands in the middle, neither the best nor the worst.
Across the fat-loss peptide class the dividing line is whether a compound has a demonstrated indication, like tesamorelin's approval for visceral fat, or is only mechanistically appealing, and AOD-9604 lands on the mechanistically-appealing side despite having reached human testing.
The safety and regulatory contrast is less about a specific known danger and more about the entire framework of oversight. Approved treatments passed regulatory review, are manufactured under enforced pharmaceutical quality standards, and carry a documented adverse-event profile that a prescriber can monitor and act on. AOD-9604 has none of that scaffolding for weight loss.
| Oversight dimension | Approved fat-loss treatments | AOD-9604 |
|---|---|---|
| Regulatory review | Passed, with a defined label | None as a weight-loss drug |
| Manufacturing | Enforced pharmaceutical quality standards | Gray-market; identity, purity, dose, sterility not guaranteed |
| Adverse-event record | Documented across large trials and post-market surveillance | Thin; the program was small and stopped early |
| Dispensing | Prescription, with prescriber monitoring | Direct online research-compound purchase |
Approved fat-loss treatments carry regulatory review, enforced manufacturing standards, a documented adverse-event profile, and prescriber monitoring, while AOD-9604 is sold as an unregulated research compound whose purity, dose accuracy, and long-term safety are undocumented rather than proven absent.
Cost and access run in nearly opposite directions for these two options, and the headline numbers mislead when they are divorced from value. The approved GLP-1 agonists carry a high list price and run through a prescriber and pharmacy with insurance coverage that varies widely, while AOD-9604 is cheaper per vial and bought directly online without a prescription. The sticker-price advantage collapses once demonstrated effect is counted.
Approved GLP-1 agonists command a premium list price of several hundred dollars a month for a demonstrated, regulator-reviewed effect and a controlled supply chain, while AOD-9604's lower per-vial price buys an unproven compound that failed to beat placebo and carries no quality guarantee.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
